KRAS and non-small cell lung carcinoma: Of the 259 patients with NS-NSCLC with valid or available NGS analysis (n = 242), driver molecular alterations were detected as follows (Figure 2): EGFR, 44 (18.2%); KRAS, 61 (25.4%), BRAF, 15 (6.3%); ALK 10 (4.3%); ERBB2, 4 (1.7%); MET, 4 (1.7%); ROS1 11 (2.3%); RET, 9 (1.9%), and NTRK, 2 (0.8%), with additional alterations detected with an incidence below 1% (e.g., IDH1, CDKN2A, FGFR3, KIT, MTOR, FGFR4.